CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Immune Design Corp. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Immune Design Corp.
1616 Eastlake Avenue E
Suite 310
Phone: (650) 392-8350p:650 392-8350 Seattle, WA  98102-3739  United States Fax: (206) 682-0648f:206 682-0648

This company ceased filing statements with the SEC on 4/12/2019.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. The Company has engineered its technologies to activate the immune system's natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer. The Company is engaged in developing multiple product candidates from its two discovery platforms, ZVex and GLAAS. Its primary product candidates, CMB305 and G100, utilize multiple immuno-oncology approaches and are in multiple Phase I and Phase II trials. CMB305 is targeting the NY-ESO-1 tumor antigen, in which a priming agent called LV305 from its ZVex platform is dosed sequentially with an agent from its GLAAS platform. G100 leverages the range of endogenous antigens found in the tumor microenvironment, including neoantigens.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/201812/31/2018YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Edward E.Penhoet 79 1/1/2013 6/1/2008
President, Chief Executive Officer, Director Carlos V.Paya 59 5/1/2011 5/1/2011
Executive Vice President, Strategy & Finance Stephen R.Brady 48 5/31/2015 9/1/2013
10 additional Officers and Directors records available in full report.

Business Names
Business Name
IMDZ
Immune Design

General Information
Number of Employees: 48 (As of 12/31/2018)
Outstanding Shares: 48,365,248 (As of 3/8/2019)
Shareholders: 17
Stock Exchange: NASD
Federal Tax Id: 262007174
Fax Number: (206) 682-0648


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023